Stockreport

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF improved progression-free survival versus current first-line standard of care in HER2 positive metastatic breast cancer TOKYO & MUNICH, January 19, 2026 BUSINESS WIRE [Read more]